Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cryosite Limited ( (AU:CTE) ) has provided an update.
Cryosite Limited reported a strong financial performance for FY25, marked by record revenues and operational achievements. The company launched a new Ultra-Frozen and Cryogenic revenue segment, positioning itself strategically in the healthcare industry. With a 12% increase in revenue to $14.1 million and a 19% rise in EBITDA to $3.4 million, Cryosite is expanding its capacity to meet growing client demand without requiring additional capital. The company also achieved significant growth in its Ultra-Frozen and Cryogenic segment, with a 58% increase in revenue, and is actively pursuing expansion opportunities to capitalize on the projected growth in biotechnology and advanced therapy medicinal products.
The most recent analyst rating on (AU:CTE) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.
More about Cryosite Limited
Cryosite Limited is a leading Australian provider specializing in Ultra-Frozen and Cryogenic temperature storage and logistics, catering to advanced pharmaceutical developments. The company leverages over two decades of experience, focusing on supporting the evolving healthcare landscape with its robust infrastructure and scientific capabilities.
Average Trading Volume: 6,948
Technical Sentiment Signal: Buy
Current Market Cap: A$36.61M
For a thorough assessment of CTE stock, go to TipRanks’ Stock Analysis page.